|
gptkbp:instanceOf
|
gptkb:gene_therapy
gptkb:drug
|
|
gptkbp:approvalYear
|
2021-03-26
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XL10
|
|
gptkbp:blackBoxWarning
|
cytokine release syndrome
neurologic toxicities
|
|
gptkbp:form
|
cell suspension
|
|
gptkbp:genericName
|
gptkb:idecabtagene_vicleucel
|
|
gptkbp:indication
|
multiple myeloma
relapsed or refractory multiple myeloma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:bluebird_bio
gptkb:Bristol_Myers_Squibb
|
|
gptkbp:mechanismOfAction
|
targets BCMA (B-cell maturation antigen)
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
infections
neutropenia
neurotoxicity
thrombocytopenia
cytokine release syndrome
|
|
gptkbp:storage
|
cryopreserved
|
|
gptkbp:target
|
gptkb:BCMA
|
|
gptkbp:treatment
|
autologous cell therapy
|
|
gptkbp:website
|
https://www.abecma.com/
|
|
gptkbp:bfsParent
|
gptkb:CAR-T_therapy
gptkb:Chimeric_Antigen_Receptor_T-cell_therapies
gptkb:Idecabtagene_vicleucel
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Abecma
|